Zobrazeno 1 - 10
of 192
pro vyhledávání: '"Michelle E, Melisko"'
Publikováno v:
Cancer Medicine, Vol 12, Iss 22, Pp 20906-20917 (2023)
Abstract Background Comorbidities and symptoms in metastatic breast cancer patients impact treatment decisions and influence prognosis and quality of life. The objective of this study is to examine the concordance between physician documentation and
Externí odkaz:
https://doaj.org/article/3817f554d5424960bec2e9f8d47b0a75
Autor:
Karen Lisa Smith, Carolyn Mead‐Harvey, Gina L. Mazza, Eileen H. Shinn, Elizabeth S. Frank, Michelle E. Melisko, Cyd Eaton, Yisi Liu, Jeannine M. Salamone, Teri Pollastro, Patricia A. Spears, Nicole E. Caston, Antonio C. Wolff, Gabrielle Betty Rocque
Publikováno v:
Cancer Medicine, Vol 13, Iss 5, Pp n/a-n/a (2024)
Abstract Background Breast cancer patients experienced heightened anxiety during the pandemic. Also, modifications to clinical trial activities allowing for virtual platforms, local assessments, and greater flexibility were introduced to facilitate p
Externí odkaz:
https://doaj.org/article/39e75f7a8dae4b6cbd9def0c113298bc
Autor:
Mary Kathryn Abel, Michelle E. Melisko, Hope S. Rugo, A. Jo Chien, Italia Diaz, Julia K. Levine, Ann Griffin, Joseph McGuire, Laura J. Esserman, Hala T. Borno, Rita A. Mukhtar
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-3 (2021)
Abstract Enrollment in metastatic breast cancer trials usually requires measurable lesions, but patients with invasive lobular carcinoma (ILC) tend to form diffuse disease. We found that the proportion of patients with metastatic ILC enrolled in clin
Externí odkaz:
https://doaj.org/article/5ae74b962d5a4b5e99550871185eb4e4
Autor:
Manuela Terranova-Barberio, Nela Pawlowska, Mallika Dhawan, Mark Moasser, Amy J. Chien, Michelle E. Melisko, Hope Rugo, Roshun Rahimi, Travis Deal, Adil Daud, Michael D. Rosenblum, Scott Thomas, Pamela N. Munster
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-10 (2020)
ER-positive breast cancer patients do not usually respond to immunotherapy. In this phase II clinical trial, the authors report the safety and efficacy of combining vorinostat and pembrolizumab with tamoxifen in ER-positive breast cancers and provide
Externí odkaz:
https://doaj.org/article/64f0fec706954f5c93dba4c047a3944a
Autor:
Laura A. Huppert, Zak Walker, Moming Li, Mi-Ok Kim, Jennifer Callan, Danielle Brandman, Melanie Majure, Michelle E. Melisko, Hope S. Rugo, Spencer Behr, A. Jo Chien
Publikováno v:
Breast Cancer Research and Treatment. 197:137-148
Pseudocirrhosis is a term used to describe changes in hepatic contour that mimic cirrhosis radiographically, but lack the classic pathologic features of cirrhosis. This radiographic finding is frequently found in patients with metastatic breast cance
Autor:
Nancy U Lin, Diana Lueftner, Adam M Brufsky, Sara M Tolaney, Michelle E Melisko, Frankie Ann Holmes, Ahmad Awada
Publikováno v:
Cancer Research. 82:P2-13
Background: Among patients (pts) with HER2+ early breast cancer (EBC), the CNS continues to serve as a sanctuary for distant metastases following trastuzumab-based adjuvant treatment (von Minckwitz 2017, Piccart 2020, von Minckwitz 2019). Since the i
Autor:
Denise M. Wolf, Jane Perlmutter, Judy C. Boughey, A. Jo Chien, Meredith Buxton, Gillian L. Hirst, Douglas Yee, Angela DeMichele, Andres Forero-Torres, Scott M. Berry, Erin D. Ellis, Anthony D. Elias, Julia Wulfkuhle, Michael Alvarado, Christina Yau, Stacy L. Moulder, Nola M. Hylton, Rita Nanda, Amy Wilson, Adam Asare, Debu Tripathy, Claudine Isaacs, Melissa Paoloni, Rosa I. Gallagher, Laura J. Esserman, Richard Schwab, W. Fraser Symmans, Cheryl Ewing, Laura J. van't Veer, Jeffrey B. Matthews, Teresa Helsten, Julia L. Clennell, Barbara Haley, Emanuel F. Petricoin, Katherine Steeg, Smita Asare, Ashish Sanil, Rachel L. Yung, Erin P. Crane, Erin Roesch, Hyo S. Han, Ruby Singhrao, Michelle E. Melisko, Hope S. Rugo, Kathy S. Albain, Donald A. Berry, Anne M. Wallace, Julie E. Lang, Amy S. Clark, Kathleen Kemmer, Lamorna Brown-Swigart
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Nature communications, vol 12, iss 1
Nature Communications
Nature communications, vol 12, iss 1
Nature Communications
HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence: ad
Autor:
William F. Pirl, Tara Sanft, Michelle E. Melisko, Karen L. Syrjala, Debra L. Friedman, Patricia A. Ganz, Halle C. F. Moore, Norah Lynn Henry, Phyllis C. Zee, Nazanin Khakpour, Divya Koura, Gregory A. Broderick, Natalie Moryl, M. Alma Rodriguez, Kristin Dickinson, Mindy Goldman, K. Scott Baker, Sophia K. Smith, Saro H. Armenian, Amye J. Tevaarwerk, Deborah A. Freedman-Cass, Linda Overholser, Kathryn J. Ruddy, Melissa M. Hudson, Kathi Mooney, Andrew T. Day, Lindsay L. Peterson, Lillie D. Shockney, Christine E. Hill-Kayser, Chirayu G. Patel, Tracey O'Connor, Electra D. Paskett, Allison L. McDonough, Wendy Demark-Wahnefried, Lidia Schapira, Javid Moslehi, Crystal S. Denlinger, Shannon M. Ansbaugh, Nicole R. McMillian
Publikováno v:
Journal of the National Comprehensive Cancer Network. 19:676-685
The NCCN Guidelines for Survivorship are intended to help healthcare professionals working with cancer survivors to ensure that each survivor’s complex and varied needs are addressed. The Guidelines provide screening, evaluation, and treatment reco
Autor:
Andre Dempsey, Laura J. van't Veer, Amrita Basu, Michelle E. Melisko, Laura J. Esserman, Nickolas Dreher, Mandy Che, Madeline B. Matthys
Publikováno v:
Cancer. 127:2342-2349
Background Symptom burden and reduced quality of life (QOL) are considerable hurdles in oncology. The authors used the Patient-Reported Outcomes Measurement Information System (PROMIS), which assesses physical and psychosocial health, to establish a
Autor:
Rebecca G. Bagley, Denise A. Yardley, Volker Möbus, Abdel-Baset Halim, Rita Nanda, Gail S. Wright, Andres Forero-Torres, Thomas Hawthorne, Javier Cortes, Alberto J. Montero, Linda T. Vahdat, Kimberly L. Blackwell, Michelle E. Melisko, Melinda L. Telli, Yi He, Peter Schmid, Cynthia X. Ma, Christopher D. Turner
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021)
Scientia
NPJ Breast Cancer
Scientia
NPJ Breast Cancer
Breast cancer; Cancer Càncer de mama; Càncer Cáncer de mama; Cáncer The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negat